LivaNova PLC (NASDAQ:LIVN)
| Market Cap | 4.11B+40.2% |
| Revenue (ttm) | 1.47B+12.4% |
| Net Income | 188.58M+189.2% |
| EPS | 3.39+187.1% |
| Shares Out | 54.93M |
| PE Ratio | 21.61 |
| Forward PE | 15.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 91,742.128 |
| Open | 75.45 |
| Previous Close | 75.93 |
| Day's Range | 74.23 - 75.45 |
| 52-Week Range | 48.82 - 85.76 |
| Beta | 0.88 |
| Analysts | Buy |
| Price Target | 93.33(+24.73%) |
| Earnings Date | Nov 4, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About LIVN
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$LIVN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in LIVN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LIVN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LIVN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
LIVN Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New LIVN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LIVN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in LIVN
| ETF | Est. Holding Size |
|---|---|
| AVUVAvantis U.S. Small Cap Value ETF | $120.38M |
| IWMiShares Russell 2000 ETF | $111.72M |
| VXFVanguard Extended Market ETF | $50.94M |
| DFATDimensional - US Targeted Value ETF | $38.52M |
| XMMOInvesco S&P MidCap Momentum ETF | $34.18M |
| DFASDimensional - US Small Cap ETF | $31.72M |
Estimated from each fund’s disclosed top holdings × AUM
LIVN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from LIVN’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score